Skip to content
Search

Latest Stories

WHO stops hydroxychloroquine trials over safety concerns

THE WHO suspended trials of the drug that Donald Trump has promoted as a coronavirus defence, fuelling concerns about the US president's handling of the pandemic that has killed nearly 100,000 Americans.

Trump has led the push for hydroxychloroquine as a potential shield or treatment for the virus, which has infected nearly 5.5 million people and killed 345,000 around the world, saying he took a course of the drug as a preventative measure.


Brazilian president Jair Bolsonaro has also heavily promoted hydroxychloroquine while the virus has exploded across nation, which this week became the second most infected in the world after the US.

But the World Health Organization said Monday (25) it was halting testing of the drug for COVID-19 after studies questioned its safety, including one published Friday that found it actually increased the risk of death.

The WHO "has implemented a temporary pause... while the safety data is reviewed", its chief Tedros Adhanom Ghebreyesus said, referring to the hydroxychloroquine arm of a global trial of various possible treatments.

Trump announced last week he was taking the drug, explaining he had decided to take after receiving letters from a doctor and other people advocating it.

"I think it's good. I've heard a lot of good stories," Trump told reporters then, as he declared it safe.

Trump dismissed the opinions then of his own government's experts who had warned of the serious risks associated with hydroxychloroquine, with the Food and Drug Administration highlighting reported poisonings and heart problems.

Trump has been heavily criticised for his handling of the virus, after initially downplaying the threat and then repeatedly rejecting scientific analysis.

The US has by far the world's highest coronavirus death toll, reaching 98,218 on Monday, with more than 1.6 million confirmed infections.

Despite the WHO suspension, Brazil's health ministry said Monday it would keep recommending hydroxychloroquine for COVID-19.

"We're remaining calm and there will be no change," health ministry official Mayra Pinheiro told a news conference.

Bolsonaro is a staunch opponent of lockdown measures and like Trump has played down the threat of the virus, even as Latin America has emerged as the new global virus hotspot.

Brazil has reported nearly 375,000 cases, widely considered to be far fewer than the real number because of a lack of testing, and more than 23,000 deaths.

Chile also is in the grip of a virus surge, with a record of nearly 5,000 infections in 24 hours on Monday.

While South America and parts of Africa and Asia are only just beginning to feel the full force of the pandemic, many European nations are easing lockdowns as their outbreaks are brought under control.

In hard-hit Spain, Madrid and Barcelona on Monday emerged from one of the world's strictest lockdowns, with parks and cafe terraces open for the first time in more than two months.

Elsewhere, gyms and swimming pools reopened in Germany, Iceland, Italy and Spain.

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Dickie and Watt

Dickie and Watt launched BrewDog at the age of 24

Getty Images

BrewDog co-founder Martin Dickie leaves after 17 years as James Watt steps back

Highlights:

  • Martin Dickie has announced his departure from BrewDog and the alcohol industry.
  • He co-founded the Ellon-based brewer with James Watt in 2007.
  • Dickie cited family time and personal reasons for his exit.
  • His departure follows recent bar closures as part of a company restructuring.
  • BrewDog confirmed no further leadership changes will follow.

BrewDog co-founder Martin Dickie has announced he is leaving the Scottish brewer and the wider alcohol industry for “personal reasons.” Dickie, who founded the Ellon-based business with James Watt in 2007, said he wanted to spend more time with his family after more than two decades in brewing and distilling.

Early beginnings

Dickie and Watt launched BrewDog at the age of 24, starting from a garage in Fraserburgh and selling hand-filled bottles from a van at local markets. The company grew rapidly to become one of the UK’s best-known craft brewers.

Keep ReadingShow less